Allergy Therapeutics Seeks Cancelation of London Listing

MT Newswires · 1d ago
03:24 AM EST, 11/17/2026 (MT Newswires) -- Allergy Therapeutics (AGY.L) proposed the cancelation of its listing on the London stock exchange's AIM segment and re-registration as a private limited company. The British biotechnology company's plan is subject to the approval of shareholders who own at least 75% of the votes to be cast at its annual general meeting on Dec. 14, according to a Tuesday filing. The board secured verbal commitments from SkyGem and Southern Fox, which together own an 87.98% interest in Allergy Therapeutics, regarding their support of the cancelation and re-registration.